Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000005

Enrollment

Registered

2009-03-13

Start date

2008-03-30

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar Hereditary Ataxia Type 2

Interventions

Will be conformed two treatment groups according to an aleatory list. One group will receive Vimang® (orally) to a daily dose of 1 800 mg, divided in two pills (300 mg each) three times a day, far fro

Mangifera indica

Exercise Therapy

Neuroprotective Agents

Antioxidants

Tablets

Administration, Oral

Placebos

Vimang®

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patients with diagnosis of SCA2 of any sex from 18 up to 60 years old, both inclusive. 2. Patient able to develop basic activities of the daily life with independence (according to Barthel scale). 3. Time of evolution of the illness until or smaller than 15 years. 4. Patient that voluntarily accept to participate in the clinical trial, by means of the signature of the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with antecedents of alcoholism. 2. Patients with antecedents of any other illness with repercussion in the nervous system. 3. Patient with non controlled chronic illnesses. 4. Pregnancy or nursing. 5. Patient with renal or hepatic failure. 6. Patients with inmunosupresores tratment or with other antioxidant treatment. 7. Patients that participate in another clinical trial.

Design outcomes

Primary

Measure	Time frame
Latency of the saccade velocity. This variable will be measured to the beginning, to the 3 months and the 6 months.	—

Secondary

Measure	Time frame
Degree of motor coordination. This variable includes: -equilibrium -march Electrophysiological variables: a) Saccade velocity b) Studies of Peripheric and Sensitive Nervous Conduction of the sural and medium nerves: PESS of medium nerve with registration in tip Erb, N13 and N20, to all will be measured latency and conduction speed. c)Intervalometry in spontaneous breathings: It will be measured mean, standard deviation and the indexes of high-low frequency of the successive differences. These variables will be measured to the beginning, to the 3 months and the 6 months.	—

Measure

Time frame

Degree of motor coordination. This variable includes: -equilibrium -march Electrophysiological variables: a) Saccade velocity b) Studies of Peripheric and Sensitive Nervous Conduction of the sural and medium nerves: PESS of medium nerve with registration in tip Erb, N13 and N20, to all will be measured latency and conduction speed. c)Intervalometry in spontaneous breathings: It will be measured mean, standard deviation and the indexes of high-low frequency of the successive differences. These variables will be measured to the beginning, to the 3 months and the 6 months.

—

Countries

Cuba

Contacts

Public ContactMariela Guevara-Garcia

Center of Pharmaceutical Chemistry

marielaguevara@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026